Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 6, 2026

Stock market today: Dow, S&P 500, Nasdaq sink after jobs report surprise as oil jumps

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq sink after jobs report surprise as oil jumps US stocks tumbled on Friday as the key monthly jobs report surprised to the downside and oil prices jumped amid fresh fears about a hit to supply from the expanding Middle East conflict…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Oil prices could surge to $150 a barrel

    80% confidence

  • Waiting for another 10% drop to Make Tech Value Again

    80% confidence

  • Increased adoption of AI tools by enterprise clients is driving demand for custom chips that power data centers

    80% confidence

  • The US will issue a waiver allowing India to buy Russian oil stranded at sea

    80% confidence

  • All Gulf energy exporters would shut down production within days

    80% confidence

  • The war on Iran would force Gulf exporters to shut off production within days

    80% confidence

  • The conflict in the Middle East could bring down the economies of the world

    80% confidence

  • The turnaround in healthcare jobs is attributed to a large labor strike at Kaiser Permanente in February

    80% confidence

  • The only path to resolution in Iran is unconditional surrender

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com